Amazon’s VMS Policy Mirrors US FDA Rules But May Reflect Stronger Industry Compliance

Amazon’s requirements reach to guaranteeing ingredients are compliant with FDA regulations. While the agency, for the most part, isn’t preventing sales of supplements containing ingredients that have not been notified as NDIs with proof of reasonable expectation of safety, Amazon could ask marketers for the information.

Amazon Inc. copies US Food and Drug Administration regulations with its requirements for dietary supplement labeling and good manufacturing practices compliance, but firms could incur more damage by crossing the e-commerce behemoth’s line rather than the agency’s.

“If Amazon conducts their own diligence, relative to what manufactures are required to attest to, and holds manufacture’s accountable, then yes, Amazon might succeed where the agency has been reluctant to act, then yes,” said Robert Durkin,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By 

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By 

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By 

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

More from Wellness

Kennedy’s Balancing Act: Push MAHA, Trim Regs

 

Same-day announcements of RFIs from HHS secretary cover nutrient review process for infant formula and Kennedy’s “10-to-1 deregulatory policy” as part of president’s “broader federal effort to reduce regulatory burdens and increase transparency.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By 

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By 

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.